ROSEWOOD (NCT03332017) is a Phase 2, open-label, randomized trial of zanubrutinib combined with obinutuzumab compared with obinutuzumab monotherapy in patients with relapsed/refractory (R/R) follicular lymphoma (FL).
Reading
BGB-3111-206 (NCT03206970) is a Phase 2, multicenter, single-arm, open-label trial of zanubrutinib in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL).
Reading
MAGNOLIA (NCT03846427) is a Phase 2, multicenter, open-label, single-arm trial of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).
Reading
ALPINE (NCT03734016) is a global, Phase 3, randomized trial comparing zanubrutinib with ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Reading
SEQUOIA (NCT03336333) is a global Phase 3, open-label, randomized study of zanubrutinib versus bendamustine plus rituximab (B+R) in patients with previously untreated chronic lymphocytic leukemia (CLL).
Reading
